Phase III Pipeline

Anticoagulants (VTE & AF) Therapeutics Market is estimated to reach $17.2 billion by 2020

Posted on

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020.

DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Anticoagulants andAtrial Fibrillation and Venous Thromboembolism. The Report majorlyemphasizes on the global Anticoagulants market size and market size of theAnticoagulants by 7 Major Markets (United States, EU5 (France, Germany,Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial

Fibrillation and Venous thromboembolism along with the market sales of the Key drugs by VTE and AF indications. It provides comprehensive review of Market Drivers, Market Barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.

Global AF market was $7.2 billion in 2015 and is expected to grow to $12.5 billion by 2020 with an compound annual growth rate (CAGR) of 11.62% where as Global VTE market was $4.2 billion in 2015 and is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%

With the recommendation of usage of novel oral anticoagulants (NOAC) by International guidelines in line with their established safety, efficacy and compliance, we expect decrease of warfarin use at a CAGR of negative 3.20% from 2015-2020 due to patient preferences in switching from warfarin to NOAC at a significant rate.  Novel Oral Anticoagulants (NOAC) will continue to be first-line oral agents, accounting for 70% of major-market sales in 2015.

Insights from recent studies clearly indicates that Physicians are relatively satisfied with the NOACs due to its efficacy and positive safety profiles without the need for anticoagulation monitoring and
dose frequencies. Conventional therapies (i.e., Warfarin) will remain entrenched as first-line therapies for most of the AF and VTE patients, followed by novel oral anticoagulants (NOAC) in the developing and underdeveloped countries due to the high cost of NOAC medications.

For more information on this report email us at info@delveInsight.com.

DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Advertisements

Global atrial fibrillation market is expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%

Posted on

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa.

DelveInsight Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 provides an overview of Atrial Fibrillation indication. The Report majorly emphasize on the global Anticoagulants market size and market size of the Anticoagulants by 7Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial Fibrillation along with the market sales of the Key drugs by AF.  The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

With the new guideline by regulatory agencies has promoted the use of NOACs over warfarin. Atrial Fibrillation guidelines has also encouraged to use CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower risk patients to receive anticoagulant treatment.

For more information email us @ info@delveinsight.com.

Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015

Posted on Updated on

Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA.

It is an autoimmune disorder when body’s own immune cell starts attacking healthy cells. This results in inflammation. It is also known as “systemic onset juvenile rheumatoid arthritis”It makes the joints inflamed and stiff for more than six weeks.

DelveInsight report on Systemic Juvenile Idiopathic Arthritis provides comparative study of drugs under development. The report provides assessment of Tofacitinib pipeline drug by Pfizer Phase III. In addition to this, the report imparts information on several other drugs as well.

Key Highlights of Report:

  • Comprehensive insights about pipeline drugs across this indication
  • Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages
  • Therapeutics assessment by monotherapy and combination products and molecule type drug information
  • Companies involved in therapeutic development of the products
  • Discontinued and dormant products

DelveInsight is offering the Report at a price of US 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

.

Infectious Disease and Vaccines Pipeline Reports

Posted on Updated on

berries

DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports.

VISIT OUR WEBSITE

Infectious Diseases and Vaccines

The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a first vaccine, and even routine vaccinations, such as those for influenza can be improved in terms of safety and efficacy. Such unmet needs are driving the continued development of ID vaccines.

Get  Notified About Whats in Others Pipeline

The research work for curing Infectious disease has rapidly assumed a prioritized role within the overall scientific portfolio. The number of vaccines development underway has increased substantially for the HCV, HIV, Tuberculosis and Influenza infections.

Get notified about all the under development vaccines worldwide and the technology they are using, stage of development, their targets, mechanism of action with our Pipeline reports. The best strategic report that will not even give you the overall developing drug profiles but also therapeutic assessment and comparative analysis at every step such as monotherapy, combination, route of administration.

Pipeline Insights Reports

HCV Vaccine-Pipeline Insights, 2014 

HIV Vaccine-Pipeline Insights, 2014 

Influenza Vaccine-Pipeline Insights, 2014 

Tuberculosis Vaccine-Pipeline Insights, 2014

ASK FOR SAMPLE PAGES NOW

For further information email us at info@delveinsight.com

Metastatic Prostate Cancer-Pipeline Insights, 2014

Posted on Updated on

DelveInsight’s,“ Metastatic Prostate Cancer-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides information on the therapeutic development based on the Metastatic Prostate Cancer dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Scope
– The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
– The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
– Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and also provide company profiling
– The report also gives the information of dormant and discontinued pipeline projects
– Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Metastatic Prostate Cancer
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
– Developing strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
– Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Contents
– Metastatic Prostate Cancer Overview
– Metastatic Prostate Cancer Pipeline Therapeutics
– Metastatic Prostate Cancer Therapeutics under Development by Companies
– Metastatic Prostate Cancer Late Stage Products (Filed and Phase III)
– Comparative Analysis
– Metastatic Prostate Cancer Mid Clinical Stage Products (Phase II)
– Comparative Analysis
– Metastatic Prostate Cancer Early Clinical Stage Products (Phase I and IND Filed)
– Comparative Analysis
– Metastatic Prostate Cancer Discovery and Pre-Clinical Stage Products
– Comparative Analysis
– Drug Candidate Profiles
– Metastatic Prostate Cancer – Therapeutics Assessment
– Assessment by Monotherapy Products
– Assessment by Combination Products
– Assessment by Route of Administration
– Assessment by Molecule Type
– Metastatic Prostate Cancer – Discontinued Products
– Metastatic Prostate Cancer – Dormant Products
– Companies Involved in Therapeutics Development for Metastatic Prostate Cancer
– Appendix
– Methodology
– Contact Us
– Disclaimer

List of Tables

– Number of Products under Development for Metastatic Prostate Cancer, 2014
– Number of Products under Development by Companies
– Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
– Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
– Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
– Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
– Drug Candidates Profiles
– Metastatic Prostate Cancer Assessment by Monotherapy Products
– Metastatic Prostate Cancer Assessment by Combination Products
– Metastatic Prostate Cancer Assessment by Route of Administration
– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
– Metastatic Prostate Cancer Assessment by Molecule Type
– Metastatic Prostate Cancer Assessment by Stage and Molecule Type
– Metastatic Prostate Cancer Therapeutics – Discontinued Products
– Metastatic Prostate Cancer Therapeutics – Dormant Products
– Products under Development by Companies, 2014

List of Figures

– Number of Products under Development for Metastatic Prostate Cancer, 2014
– Late Clinical Stage Products (Filed and Phase III), 2014
– Mid Clinical Stage Products (Phase II), 2014
– Early Clinical Stage Products (Phase I and IND Filed), 2014
– Discovery and Pre-Clinical Stage Products, 2014
– Metastatic Prostate Cancer Assessment by Monotherapy Products
– Metastatic Prostate Cancer Assessment by Combination Products
– Metastatic Prostate Cancer Assessment by Route of Administration
– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
– Metastatic Prostate Cancer Assessment by Molecule Type
– Metastatic Prostate Cancer Assessment by Stage and Molecule Type

Report Pricing
Single User License: $1250
Site License:$2500
Global License:$4000

For Sample Pages and Report, please contact us at info@delveinsight.com

DelveInsight’s Marketed and Pipeline Reports Going Viral!

Posted on Updated on

If a market is growing enormously, you need to understand what’s nourishing it

 

DelveInsight Report

DelveInsight has launched its Reports under two brands Pharm Delve and Pharm Insights.

Pharm Delve reports are known for its extensive detailed information of the Marketed drugs– Global Market, API Market & Manufacturers across the US, Europe and Asia specifically China and India and Phase III Pipeline drugs information. These reports provide whole list of companies interested in your business. It gives you the most up to date information on drug marketed data, patent data, upcoming API with lots of potential in market, interested Generic Drug Companies, Active Pharmaceutical Ingredient (API) Manufacturers to determine which companies and therapies are emerging leaders while understanding the market needs.

Pharm Insights covers the pipeline reports. Mechanism of Action Reports launched has become the most known and on demand amongst the clients. The report has highlighted all the under development drugs falling under the specific MOA with the comparative analysis at various stages and therapeutics assessment by monotherapy and combination products and molecule type drug information. The reports have covered each and every detail of the drugs while chemical information and company profile are considered thoroughly.

Five worth Reason for Spending on these Reports

  1. Track your closest Competitors
  2. Identifying potential customers
  3. Prioritizing new drug intermediates to add to the portfolio
  4. Uncovering opportunities Globally
  5. Organic as well as Inorganic Growth

Who can buy these Reports?

  • Pharma Companies
  • Drug Development Companies
  • Generic Manufacturing Companies
  • API Manufacturers
  • Institutions/Universities

 Where to buy?

You can buy these reports from the resellers given : Report Buyer, Report Linker, ASD Media, VPG Market Research, Market Publishers, Bharat Book Bureau and Report stack

About DelveInsight

DelveInsight is a Business consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. We provide cutting-edge market and pipeline analysis and API intelligence to the Pharma and Biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies.

At DelveInsight, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one – collaborating to reach shared goals, and developing through challenging and meaningful experiences. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing clear and forthright business recommendations to help clients evaluate potential paths and make vital decisions at all stages of a product’s lifecycle and across multiple business and therapeutic areas.